Zivo Bioscience, Inc.

ZIVO

Zivo Bioscience, Inc.

ZIVO

Insider Sentiment (TTM):

Last Purchase:2026-04-17Last Sale:2025-04-08Shares Purchased (TTM):214,626Shares Sold (TTM):0

Institutional Sentiment:

As of:2025-12-31Institutional Shares Owned:4,964Shares Outstanding:3,832,327Institutional Ownership Pct.:0.13%

Earnings Market Reaction:

Filing Date:2025-11-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Assets
Assets Current
Assets Current	0	0	1	2	0	0	1	0	2	1	1	2
Cash And Cash Equivalents At Carrying Value	0	0	1	2	0	0	0	0	1	0	0	2
Accounts Receivable Net	0	0	0	0	0	0	0	0	0	0	-	0
Prepaid Expense And Other Assets Current	0	0	1	0	0	0	1	0	0	1	1	0
Property Plant And Equipment Net	-	-	-	-	-	-	-	0	0	0	0	0
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets
Other Assets	-	-	0	0	0	0	0	0	0	0	0	0
Security Deposit	0	0	0	0	0	0	0	0	0	0	0	0
Assets	1	1	1	2	0	1	1	1	2	1	1	2
Liabilities And Stockhold…
Accounts Payable Current	1	1	1	1	1	1	1	1	1	1	1	0
Customer Deposits Current	0	0	0	-	0	0	-	-	-	-	-	-
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Convertible Notes Payable	-	-	-	0	0	0	0	0	0	0	0	0
Liabilities Current
Liabilities Current	4	3	3	2	3	3	3	3	3	4	3	2
Loans Payable	-	-	-	-	0	0	0	-	1	1	1	-
Notes Payable Current	0	-	0	-	-	-	-	-	-	-	-	-
Convertible Debt Current	0	0	-	-	-	-	-	-	-	-	-	-
Other Notes Payable	0	0	0	0	-	-	-	0	-	-	-	-
Interest Payable Current	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Revenue	-	-	-	-	-	-	-	0	0	0	0	1
Accrued Liabilities Current	2	1	1	1	1	1	1	1	1	1	1	0
Liabilities Noncurrent
Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Lease Deposit Liability	0	0	0	-	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	-	-	0	0	-	-	-	0	0	0	0	0
Long Term Notes Payable	0	-	-	-	-	-	-	-	-	-	-	-
Liabilities	4	3	3	2	3	3	3	3	3	4	3	2
Equity
Commitments And Contingen…
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Additional Paid In Capital	141	140	140	136	133	131	123	121	121	117	116	116
Stockholders Equity	-3	-3	-2	-1	-2	-2	-2	-2	-1	-3	-2	-0
Retained Earnings Accumulated Deficit	-144	-143	-141	-137	-135	-133	-125	-124	-122	-120	-118	-116
Liabilities And Stockholders Equity	1	1	1	2	0	1	1	1	2	1	1	2
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	-	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	25	25	25	-	25	25	25	25	25	150	150	25
Preferred Stock Shares Issued	-	-	-	-	3	3	3	-	2	9	150	-
Common Stock Shares Issued	4	4	4	-	-	-	-	2	-	-	-	2
Shares Outstanding	4	4	4	-	3	3	3	2	2	9	9	2

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	-4.39%	-33.39%	-44.61%	-18.50%	-35.51%	-23.16%	-18.37%	-19.02%	-14.29%	-	-	-
2024	-4.60%	8.56%	8.56%	28.21%	118.88%	127.27%	-9.53%	2.09%	-7.91%	-15.73%	-10.34%	-3.31%
2023	-13.25%	-23.66%	-38.17%	0.00%	-50.27%	-79.95%	-34.04%	100.00%	410.64%	-10.12%	-11.14%	-10.46%
2022	-	-	-	-	-	-	-	-	-	-6.71%	-15.24%	-16.16%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Liquidity Ratios
Current Ratio	0.08	0.14	0.39	0.80	0.17	0.17	0.23	0.15	0.61	0.14	0.33	0.94
Quick Ratio	0.02	0.01	0.20	0.76	0.07	0.00	0.05	0.10	0.47	0.01	0.07	0.89
Working Capital	-3.33M	-2.55M	-1.59M	-406.38K	-2.14M	-2.38M	-2.37M	-2.34M	-1.23M	-3.27M	-1.86M	-126.04K
Leverage & Debt
Debt to Equity	-1.17	-1.28	-1.82	-4.19	-1.24	-1.25	-1.36	-1.25	-2.92	-1.23	-1.65	-200.87
Interest Coverage TTM	-372.22	-529.37	-919.26	-743.44	-221.51	-151.12	-59.24	-65.31	-96.89	-155.79	-326.54	-343.71
Debt Ratio	6.87	4.61	2.21	1.31	5.20	4.99	3.78	4.97	1.52	5.43	2.54	1.01
Efficiency & Turnover
Asset Turnover TTM	0.36	0.33	0.11	0.14	0.04	0.04	0.07	0.02	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-2.22	-2.55	-4.35	-4.23	-4.01	-4.47	-2.58	-4.60	-	-	-0.92	-5.57
Free Cash Flow Per Share TTM	-0.80	-1.02	-1.07	-1.19	-1.18	-1.51	-1.92	-2.43	-3.75	-0.64	-0.68	-4.52
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	12.72%	-6.06%	-34.71%	38.05%	-	-	-	-	-
Operating Profit Margin TTM	-4,419.46%	-4,604.56%	-13,411.40%	-8,498.85%	-28,853.35%	-54,976.33%	-10,365.59%	-26,267.67%	-67,832.14%	-208,195.01%	-	-
Net Profit Margin TTM	-4,434.85%	-4,615.61%	-13,430.07%	-8,513.44%	-28,916.58%	-56,136.97%	-11,176.47%	-28,127.25%	-72,113.82%	-214,539.46%	-	-
Growth Metrics
Net Revenue Growth (1Y)	304.11%	792.46%	91.73%	468.61%	301.27%	482.72%	-	-	-	-	-	-
Net Income Growth (1Y)	-38.02%	-26.62%	130.39%	72.10%	60.90%	52.48%	-18.50%	-11.07%	-7.62%	-1.17%	1.46%	-0.12%
EPS Growth (1Y)	-43.55%	-36.19%	69.53%	13.22%	-19.71%	332.74%	175.20%	-41.40%	399.64%	-1.17%	1.46%	499.27%
Valuation Metrics
P/E TTM	-7.22	-5.85	-3.97	-5.82	-4.19	-1.95	-3.05	-0.37	-1.60	-15.74	-20.03	-2.69
P/B TTM	-18.65	-22.40	-40.08	-151.21	-27.55	-11.28	-9.53	-1.30	-12.42	-43.49	-99.95	-2,217.02
P/S TTM	320.25	270.21	533.56	495.22	1,211.87	1,096.97	341.17	103.39	1,151.23	33,771.23	-	-
Market Cap	61.28M	56.91M	64.83M	77.86M	57.38M	25.89M	21.62M	2.86M	13.58M	136.77M	174.08M	23.55M
Enterprise Value	61.61M	57.04M	64.75M	76.62M	57.22M	25.89M	21.48M	2.58M	12.10M	136.75M	173.87M	21.75M
Calculated Values
Free Cash Flow TTM	-3.08M	-3.90M	-4.04M	-4.31M	-4.12M	-5.01M	-5.37M	-5.80M	-6.53M	-6.05M	-6.37M	-7.10M
Net Debt	330.18K	128.69K	-77.81K	-1.24M	-159.40K	-2.47K	-138.64K	-274.38K	-1.48M	-21.07K	-208.60K	-1.80M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-17Purchase

Owner: Strome, Investment Manage…

Title: -

Shares: 100,000

Price/Share: $2.00

Value: $200,000.00

Shares Owned: 572,942

Relationship: Other

Ownership: Indirect

2026-02-27Purchase

Owner: Yaldoo, Laith L

Title: -

Shares: 1,543

Price/Share: $9.72

Value: $14,997.96

Shares Owned: 583,615

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-02-12Purchase

Owner: Strome, Group, Inc., Stro…

Title: -

Shares: 20,000

Price/Share: $9.77

Value: $195,400.00

Shares Owned: 472,942

Relationship: TenPercentOwner

Ownership: Indirect

2026-02-10Purchase

Owner: Yaldoo, Laith L

Title: -

Shares: 2,434

Price/Share: $10.27

Value: $24,997.18

Shares Owned: 582,072

Relationship: Director,TenPercentOwner

Ownership: Indirect

2026-01-26Purchase

Owner: Payne, John Bernard

Title: President and CEO

Shares: 11,709

Price/Share: $8.54

Value: $99,994.86

Shares Owned: 19,618

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-17	Strome, Investment Manage…	Other	-	Indirect	Purchase	100,000	2.00	$200,000.00	572,942	4
2026-02-27	Yaldoo, Laith L	Director,TenPercentOwner	-	Indirect	Purchase	1,543	9.72	$14,997.96	583,615	4
2026-02-12	Strome, Group, Inc., Stro…	TenPercentOwner	-	Indirect	Purchase	20,000	9.77	$195,400.00	472,942	4
2026-02-10	Yaldoo, Laith L	Director,TenPercentOwner	-	Indirect	Purchase	2,434	10.27	$24,997.18	582,072	4
2026-01-26	Payne, John Bernard	Director,Officer	President and CEO	Direct	Purchase	11,709	8.54	$99,994.86	19,618	4
2026-01-26	Cornell, Alison A	Director	-	Direct	Purchase	11,709	8.54	$99,994.86	279,481	4
2026-01-14	Maggiore, Christopher D.	Director,TenPercentOwner	-	Direct	Purchase	1,766	8.49	$14,993.34	519,292	4
2026-01-14	Yaldoo, Laith L	Director,TenPercentOwner	-	Indirect	Purchase	1,766	8.49	$14,993.34	579,638	4
2025-11-28	Yaldoo, Laith L	Director,TenPercentOwner	-	Indirect	Purchase	2,777	9.00	$24,993.00	577,872	4
2025-10-13	Strome, Investment Manage…	Other	-	Indirect	Purchase	20,259	12.34	$249,996.06	452,942	4
2025-10-10	Yaldoo, Laith L	Director,TenPercentOwner	-	Indirect	Purchase	1,659	12.05	$19,990.95	575,095	4
2025-10-08	Maggiore, Christopher D.	Director,TenPercentOwner	-	Direct	Purchase	23,682	12.01	$284,420.82	517,526	4
2025-09-30	Yaldoo, Laith L	Director,TenPercentOwner	-	Indirect	Purchase	15,322	15.99	$244,998.78	573,436	4
2025-06-13	Yaldoo, Laith L	Director,TenPercentOwner	-	Indirect	Purchase	3,488	14.33	$49,983.04	558,114	4
2025-04-08	Maggiore, Christopher D.	Director,TenPercentOwner	-	Direct	Sale	20	16.25	$325.00	507,000	4
2025-01-22	Yaldoo, Laith L	Director,TenPercentOwner	-	Indirect	Purchase	10,080	17.53	$176,702.40	554,626	4
2024-12-26	Strome, Mark E, Strome In…	TenPercentOwner	-	Indirect	Purchase	75,000	20.19	$1,514,250.00	398,683	4
2024-10-16	Yaldoo, Laith L	Director	-	Indirect	Purchase	3,133	15.96	$50,002.68	533,424	4
2024-10-16	Payne, John Bernard	Director,Officer	President and CEO	Direct	Purchase	6,343	15.76	$99,965.68	7,909	4
2024-08-27	Strome, Mark E, Strome Gr…	Other	-	Indirect	Purchase	30,000	8.44	$253,200.00	398,683	5
2024-08-22	Maggiore, Christopher D.	Director,TenPercentOwner	-	Direct	Purchase	31,336	8.34	$261,342.24	498,443	4
2024-08-22	Cornell, Alison A	Director	-	Direct	Purchase	11,990	8.34	$99,996.60	257,975	4
2024-07-26	Maggiore, Christopher D.	Director,TenPercentOwner	-	Direct	Purchase	2,080	8.05	$16,744.00	467,107	4
2024-06-12	Maggiore, Christopher D.	Director,TenPercentOwner	-	Direct	Purchase	3,764	7.97	$29,999.08	465,027	4
2024-01-02	Cornell, Alison A	Director	-	Direct	Purchase	41,666	1.20	$49,999.20	68,666	4
2023-12-29	Maggiore, Christopher D.	Director,TenPercentOwner	-	Direct	Purchase	157,692	1.30	$204,999.60	336,816	4
2023-12-13	Maggiore, Christopher D.	Director,TenPercentOwner	-	Direct	Purchase	45,000	1.00	$45,000.00	179,124	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2025-12-31

0.13%

Inst. Shares: 4,964

Shares Outstanding: 3,832,327

2025-09-30

0.12%

Inst. Shares: 4,464

Shares Outstanding: 3,832,327

2025-06-30

0.12%

Inst. Shares: 4,464

Shares Outstanding: 3,817,005

2023-12-31

0.01%

Inst. Shares: 166

Shares Outstanding: 2,382,356

2023-09-30

70.79%

Inst. Shares: 1,232,936

Shares Outstanding: 1,741,610

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2025-12-31	4,964	3,832,327	0.13%
2025-09-30	4,464	3,832,327	0.12%
2025-06-30	4,464	3,817,005	0.12%
2023-12-31	166	2,382,356	0.01%
2023-09-30	1,232,936	1,741,610	70.79%
2023-06-30	1,440,088	9,419,660	15.29%
2023-03-31	424,517	9,419,660	4.51%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Zivo Bioscience, Inc. (ZIVO) — SEC Financial Statements & Analysis

Zivo Bioscience, Inc. (ZIVO) is a biological products, (no diagnostic substances) company, incorporated in NV. Zivo Bioscience, Inc. trades on OTC as: ZIVO, ZIVOW. Based on its latest SEC filing (Form 10-Q, period ending 2025-09-30), Zivo Bioscience, Inc. reported a 304.11% year-over-year revenue growth, a Gross Profit Margin of 12.72% (TTM), a Debt-to-Equity ratio of -1.17x, a Price-to-Sales (P/S) ratio of 320.25x (TTM), a Price-to-Book (P/B) ratio of -18.65x (TTM), at a market cap of $61.28M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 304.11%
Gross Profit Margin TTM: 12.72%
Debt To Equity: -1.17x
P/S TTM: 320.25x
P/B TTM: -18.65x
Market Cap: $61.28M

Data as of 2025-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Zivo Bioscience, Inc. in?

Zivo Bioscience, Inc. (ZIVO) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ZIVO's market cap?

Zivo Bioscience, Inc. (ZIVO) has a market capitalization of $61.28M as of 2025-09-30.

What exchange does ZIVO trade on?

Zivo Bioscience, Inc. (ZIVO) trades on the OTC.

Where is Zivo Bioscience, Inc. incorporated?

Zivo Bioscience, Inc. is incorporated in NV.